Get startedLog in
    Picture of ASKA Pharmaceutical Holdings Co logo

    4886 — ASKA Pharmaceutical Holdings Co Cashflow Statement

    0.000.00%
    jp flag iconLast trade - 00:00
    HealthcareMid CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for ASKA Pharmaceutical Holdings Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    2026
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:YuhoYuhoYuhoYuhoTanshin
    Standards:
    JAS
    JAS
    JAS
    JAS    		—
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line6,1635,3579,8626,1926,991
    Depreciation
    Amortisation
    Non-Cash Items-2,485-387-3,592-1,176-1,007
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-3,721-4,747-7,446-4,222-2,766
    Change in Accounts Receivable
    Change in Inventories
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities2,8423,3501,4863,0416,303
    Capital Expenditures-2,377-746-1,453-3,562-2,874
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items9,120-3803,159-2,562-2,878
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities6,743-1,1261,706-6,124-5,752
    Financing Cash Flow Items-2—-22-1-26
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-2,996-1,820-3,943-2,956-818
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash6,589402-766-6,136-475